CT Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

CT Financial Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$273K	Buy	3,934 +1	+0%	+$67	0.17%	127
2016 Q4	$233K	Buy	3,933 +301	+8%	+$18.6K	0.15%	136
2016 Q3	$241K	Buy	3,632 +1	+0%	+$62	0.15%	129
2016 Q2	$196K	Sell	3,631 -1,278	-26%	-$70K	0.12%	145
2016 Q1	$254K	Buy	4,909 +2,449	+100%	+$127K	0.14%	122
2015 Q4	$173K	Buy	2,460 +4	+0.2%	+$273	0.1%	163
2015 Q3	$153K	Buy	2,456 +2	+0.1%	+$158	0.1%	166
2015 Q2	$206K	Sell	2,454 -264	-10%	-$20.5K	0.12%	147
2015 Q1	$204K	Sell	2,718 -135	-5%	-$9.43K	0.11%	150
2014 Q4	$177K	Buy	+2,853	New	+$163K	0.13%	124
2014 Q1	$204K	Buy	+2,718	New	+$139K	0.11%	150

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

CT Financial Advisors's XBI Position: Q1 2017 in Review

CT Financial Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.03% in Q1 2017, buying an estimated $67 and bringing the position to 3,934 shares worth $273K. The position accounts for 0.17% of the portfolio, ranked #127.

CT Financial Advisors first reported a position in XBI in Q1 2014 and has held it in 11 quarters since. 292 funds tracked by Wall St. Rank hold XBI as of Q1 2017.

CT Financial Advisors held 3,934 shares of State Street SPDR S&P Biotech ETF worth $273K as of Q1 2017.
CT Financial Advisors bought 1 State Street SPDR S&P Biotech ETF share in Q1 2017, an estimated $67.
State Street SPDR S&P Biotech ETF made up 0.17% of CT Financial Advisors's portfolio in Q1 2017, its #127 holding.
CT Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2014 and has held it in 11 quarters since.
292 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.